Navigation Links
Genmab Announces Year End 2007 Financial Results
Date:3/31/2008

Genmab Reports Financial Results for the 12 Months Ended December 31, 2007

COPENHAGEN, Denmark, March 31 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today results for the financial year ended December 31, 2007.

Revenues of DKK 530 million (approximately USD 104 million) compared to DKK 136 million (approximately USD 27 million) in 2006.

An Operating Loss of DKK 437 million (approximately USD 86 million). This compares to an Operating Loss of DKK 472 million (approximately USD 93 million) reported in 2006.

Net Financial Income totaled DKK 54 million (approximately USD 11 million) compared to Net Financial Income of DKK 34 million (approximately USD 7 million) in 2006.

A Net Loss of DKK 383 million (approximately USD 76 million) compared to a Net Loss in 2006 of DKK 438 million (approximately USD 86 million). The Net Loss per share was DKK 8.72 (approximately USD 1.72) in 2007 compared to a Net Loss per share of DKK 11.26 (approximately USD 2.22) in 2006. The 2007 Net Loss exceeded Genmab's guidance of DKK 260 to 310 million as a development milestone payment projected for late 2007 was not received until January 2008. The milestone payment of DKK 87 million was triggered by the first patient receiving treatment in the HuMax-CD20 (ofatumumab) Phase III rheumatoid arthritis (RA) program.

Genmab ended the year with a cash position of DKK 3.7 billion (approximately USD 728 million), which is an increase of approximately DKK 2.0 billion (approximately USD 388 million) from the end of 2006.

USD 1.00 = DKK 5.075 (Danish Central Bank's spot rate on December 31, 2007)

2007 Highlights:

Genmab achieved a number of business and scientific milestones, as follows:

Partnership progress:

Genmab and GlaxoSmithKline received antitrust clearance for the

HuMax-CD20 co-development and commercialization agreement; achieved first

two milestones in collaboration

Achieved
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... VIEW, Calif. , May 5, 2015  23andMe, ... launch of the Lupus Research Study in ... 5,000 individuals with systemic lupus erythematosus, more commonly known ... the genetics of lupus. The effort is also in ... with Lupus Awareness Month in May. Approximately ...
(Date:5/5/2015)... 2015 Psyche Systems Corporation and Luminate Health ... first-of-its-kind platform that helps labs comply with new federal ... the way patients engage with these results, and improves ... provides a HIPAA-compliant digital platform that gives labs an ... their lab results, and uniquely connects labs, physicians, and ...
(Date:5/5/2015)... LOS ANGELES , May 5, 2015 ... and pioneer in providing on-demand access to scientific, technical ... purchasing agreement with the Association of Southeastern Research ... of 38 research libraries located across 11 southeastern states. ... developing innovative and collaborative programs to address the continually ...
(Date:5/5/2015)... Franz Inc ., the leading supplier ... its flagship product, AllegroGraph, has been named a Champion by ... report. AllegroGraph is a high performance Semantic Graph ... Graph databases are skyrocketing in popularity and have grown by ... DBMS ranking by DB-Engines. , “We are excited ...
Breaking Biology Technology:23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 4Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3
... LAVAL, QC, Oct. 15 /PRNewswire-FirstCall/ - Neptune ... is pleased to,announce the appointment of a ... comprised of 5 renowned scientists. Neptune ... of the new,members of the Advisory Board ...
... Oct. 15 Wyeth,Pharmaceuticals, a division of Wyeth ... presented today at the 63rd Annual Meeting of ... women who received 100 mg/day or,150 mg/day of ... a significant reduction in moderate to severe,vasomotor symptoms ...
... Inc.,(Nasdaq: ORCH ), a leading worldwide provider ... quarter 2007 financial results on,Thursday, November 1, 2007 ... a,conference call and webcast to discuss the results ... will discuss financial results for the third quarter,2007 ...
Cached Biology Technology:Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board 2Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board 3Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 2Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 3Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 4Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 5Orchid Cellmark to Announce Third Quarter 2007 Financial Results on November 1, 2007 2
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... of Pennsylvania survey of dog owners who use confrontational ... have found that most of these animals will continue ... The study, published in the current issue of ... non-aversive or neutral training methods such as additional exercise ...
... Singapore Centre for Drug Discovery (LSCDD), Singapore,s National Neuroscience ... (SICS), have teamed up to advance drug discovery using ... one of the institutions of SingHealth, the largest public ... of the US-based biopharmaceutical company, Eli Lilly and Company ...
... microscopic channels called plasmodesmata that are embedded in their ... growing tips, called "meristems," the plasmodesmata are lifelines, allowing ... Developmental and environmental cues trigger changes in the ... of traffic through them. The genes and molecular pathways ...
Cached Biology News:If you're aggressive, your dog will be too, says veterinary study at University of Pennsylvania 2Singapore research organisations team up to advance drug discovery using brain tumor stem cells 2CSHL researchers identify gene that helps plant cells keep communication channels open 2CSHL researchers identify gene that helps plant cells keep communication channels open 3
Fujifilm BAS-1800II provides the ideal configuration for a low-cost imager that requires only a small amount of space in the laboratory. The small imager for accurate high-throughput screening...
When added to StemSep T Cell Enrichment cocktail, human TCRab TAC is designed to deplete human TCRab from samples to isolate gd T cells....
... 384 is a compact and self-contained ... is a unique flow-through device, which ... included wash system. Optional refill ... system. Will be upgradable to ...
... The Eclipse C1 Plus is a ... highest-quality digital imaging with an ultra-compact and ... of the C1 Plusboost optical performance to ... acquisition.The system alsoincludes support for X and ...
Biology Products: